This page shows the latest JAK1 inhibitor news and features for those working in and with pharma, biotech and healthcare.
This includes AQ280, a JAK1 small molecule inhibitor initially being assessed as a potential treatment for eosinophilic oesophagitis, an inflammatory disease of the oesophagus.
The SMC’s approval of the once-daily, oral, JAK1 preferential inhibitor is specifically for adults who have previously been treated for moderate RA.
with myelofibrosis who were symptomatic and anaemic and had been previously treated with an FDA-approved Janus kinase (JAK) inhibitor. ... Momelotinib is a JAK1/2 inhibitor, which treats symptoms of the cancer, but also targets other pathways called
The Regulus programme is working to develop a next-generation JAK1 inhibitor for eosinophilic oesophagitis. ... The Regulus programme is focused on developing a next-generation JAK1 inhibitor and Aqilion will start by testing, assessing and developing
Cibinqo is a once-daily, oral Janus kinase 1 (JAK1) inhibitor used in adult patients living with moderate-to-severe atopic dermatitis who have not yet found relief in currently available
A decision on the JAK1/2 inhibitor is expected by 22 June 2021, Incyte said in a statement. ... However, the JAK inhibitor plus standard-of-care failed to prevent complications in this patient group in the RUXCOVID study.
More from news
Approximately 1 fully matching, plus 33 partially matching documents found.
Sales are projected at $1.589bn in 2024. 5. Filgotinib from Gilead/Galapagos is an oral JAK1 inhibitor in regulatory review in the US, EU and Japan for rheumatoid arthritis Overactivation ... It will face competition mainly from generic statins and PCSK9
is its experimental JAK1 inhibitor filgotinib for rheumatoid arthritis.
Upadacitinib, from AbbVie, treats rheumatoid arthritis. Upadacitinib is an orally dosed inhibitor of an intracellular target called JAK1. ... The first-in-class inhibitor of hypoxia- inducible factor-prolyl hydroxylase, or HIFPH, was approved in December
It also unveiled mid-stage data on its JAK1 inhibitor upadacitinib in atopic dermatitis, adding another clinical win to earlier successes in rheumatoid arthritis. ... t the only oral JAK inhibitor developer with its eye on that particular prize.
Galapagos (NL). Gilead. Collaboration. licence. JAK1-selective inhibitor, filgotinib in phase II for RA and Crohn's disease . ... 825. Takeda (Respiratory). AstraZeneca. Acquisition - asset. AZ buys Takeda global respiratory business including PDE 4
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
No results were found
KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...